Piper Sandler Maintains Overweight on Revance Therapeutics, Lowers Price Target to $42-Report released on 8th Nov 2023
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst David Amsellem maintains an Overweight rating on Revance Therapeutics (NASDAQ:RVNC) but lowers the price target from $44 to $42.
November 09, 2023 | 5:04 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Piper Sandler maintains an Overweight rating on Revance Therapeutics but lowers the price target from $44 to $42.
The news is directly related to Revance Therapeutics. While the Overweight rating is maintained, indicating a positive outlook, the lowering of the price target might create some uncertainty among investors, potentially impacting the stock's short-term performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100